Contents & References of Theoretical investigation of the structure, binding and spectral characteristics of antitumor drugs of ruthenium complexes with DNA bases
List:
Abstract 1
Chapter One - Preface
1-1 Introduction. 2
1-2 background. 3
1-3 basis and basis of performance. 4
1-4 The first anti-cancer compounds. 5
1-5 ruthenium compounds with anti-cancer properties. 10
1-6 arene ruthenium complexes with anti-tumor and anti-proliferative properties. 12
1-7 Arene mononuclear ruthenium complexes containing -P or N-donor ligands 13
1-8 Interaction with DNA: What is its role in reducing cytotoxicity? 16
1-9 organometallic ruthenium complexes: breaking the law or a controversial report?. 18
10-10 Biological activity of ruthenium ions: active parts or inactive parts? 20
Chapter Two - Computational Chemistry
2-1 Introduction. 23
2-2 Schr?dinger equation. 26
2-3 calculation methods from the basis. 27
2-3-2 Correlation methods of change. 31
2-3-3 configuration interaction method. 32
2-3-4 Disturbance correlation methods. 32
2-3-5 Muller-Plast (MP) disturbance theory 33
2-3-6 open shell methods 35
2-3-7 Rutan-Hall theory. 35
2-4 Density functional theory (DFT) 36
2-5 semi-empirical method. 39
6-2 molecular mechanics method. 41
2-7 Basic set. 42
2-7-1 Minimum base set: STO-3G. 44
2-7-2 basic set of capacity of horns. 45
2-7-3 Basic sets with polarizing functions 27
2-7-4 Basic sets with penetrating functions. 47
3-6 software used 48
Chapter three - discussion and conclusion
3-1 Energetic analysis. 51
3-2 Analysis of frontal orbitals. 51
3-2-1 Shape of molecular orbitals. 52
3-3 Analysis of the structure 53
3-4 Examination of the infrared spectrum. 54
3-5 Examining the electron spectrum. 56
3-6 Temperature dependence of thermochemical properties. 57
3-7 Analysis of natural bonding orbitals. 60
3-8 atomic charges. 61
3-9 Superpolarizability. 62
Future works 65
References 66
Latin abstract. 71
Source:
A. K. Renfrew, A. D. Phillips, A. E. Egger, C. G. Hartinger, S. S. Bosquain, A. A. Nazarov, B. K. Keppler, L. Gonsalvi, M. Peruzzini and P. J. Dyson, Organometallics, 2009, 28, 1165.
A. Schaefer, H. Horn, R. Ahlrichs, J.Chem.Phys, 97, (1992), 2571.
Alberta Bergamoa and Gianni Sava, Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs, Dalton Transactions, 40, 2011, 7817-7823. A.E. Reed, F. Weinhold, J. Chem. Phys. 83 (1985) 1736–1740.
A. Dorcier, W. H. Ang, S. Bola?no, L. Gonsalvi, L. Juillerat-Jeanneret, G. Laurenczy, M. Peruzzini, A. D. Phillips, F. Zanobini and P. J. Dyson, Organometallics, 2006, 25, 4090.
A. D. Kelman, M. J. Clarke, S. D. Edmonds and H. J. Peresie, J. Clin. Hematol. Oncol. 1977, 7, 274.
A. C. G. Hotze, S. E. Caspers, D. de Vos, H. Kooijman, A. L. Spek, A. Flamigni, M. Bacac, G. Sava, J. G. Haasnoot and J. Reedijk, JBIC, J. Biol. Inorg. Chem., 2004, 9, 354.
A. H. Velders, H. Kooijman, A. L. Spek, J. G. Haasnoot, D. de Vos and J. Reedijk, Inorg. Chem., 2000, 39, 2966.
B.J.Wang, B.G.Johnson, R.J.Boyd, and L.A.Eriksson, J.phys.chem, 100, (1996) 6317.
B. Serli, E. Zangrando, T. Gianferrara, C. Scolaro, P. J. Dyson, A. Bergamo and E. Alessio, Eur. J. Inorg. Chem., 2005, 3423.
B. Dutta, C. Scolaro, R. Scopelliti, P. J. Dyson and K. Severin, Organometallics, 2008, 27, 1355.
C. S. K. Rajapakse, A. Mart´?nez, B. Naoulou, A. A. Jarzecki, L. Su´arez, C. Deregnaucourt, V. Sinou, J. Schr´
C. A. Vock, W. H. Ang, C. Scolaro, A. D. Phillips, L. Lagopoulos, L. Juillerat-Jeanneret, G. Sava, R. Scopelleti and P. J. Dyson, J. Med.Chem., 2007, 50, 2166.
C. Manzotti, G. Pratesi, E. Menta, R. D. Domenico, E. Cavaletti, H. H. Fiebig, L. R. Kelland, N. Farrell, D. Polizzi, R. Supino, G. Pezzoni and F. Zunino, Clin. Cancer Res., 2000, 6, 2626.
C. A. Vock, C. Scolaro, A. D. Phillips, R. Scopelleti, G. Sava and P.. J. Dyson, J. Med. Chem., 2006, 49, 5552.
C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G. Laurenczy, T. J. Geldbach, G. Sava and P. J. Dyson, J. Med. Chem., 2005, 48, 4161.
C. S. Allardyce, P. J. Dyson, D. E. Ellis, P. A. Salter and R. Scopelliti, J. Organomet. Chem., 2003, 668, 35.
C. A. Vock, A. K. Renfrew, R. Scopelliti, L. Juillerat-Jeanneret and P. J. Dyson, Eur. J. Inorg. Chem., 2008, 1661.
C. Scolaro, T. J. Geldbach, S. Rochat, A. Dorcier, C. Gossens, A. Bergamo, M. Cocchietto, I. Tavernelli, G. Sava, U. Rothlisberger and P. J. Dyson, Organometallics, 2006, 25, 756.
D. Chatterjee, A. Mitra and G. S. De, Platinum Met. Rev., 2006, 50,
e.lewars,Computationalchemistry,Kluweracademicpublishers,boston,2003,pp.225-229
evel, E. Musi, G. Ambrosini,G. K. Schwartz and R.A. Sanchez-Delgado, Inorg. Chem., 2009, 48, 1122.
E. Alessio, G. Mestroni, G. Nardin, W. M. Attia, M. Calligaris, G. Sava and S. Zorzet, Inorg. Chem., 1988, 27, 4099.
F. Kratz, M. Hartmann, B. K. Keppler and L. Messori, J. Biol. Chem., 1994, 269, 2581.
F. Wang, H. Chen, J. A. Parkinson, P. d. S. Murdoch and P. J. Sadler, Inorg. Chem., 2002, 41, 4509. F. Wang, J. Bella, J. A. Parkinson and P. J. Sadler, JBIC, J. Biol. Inorg. Chem., 2005, 10, 147.
F. Wang, H. Chen, S. Parsons, I. D. H. Oswald, J. E. Davidson andP. J. Sadler, Chem.–Eur. J., 2003, 9, 5810.
G. Sava, S. Pacor, S. Zorzet, E. Alessio and G. Mestroni, Pharmacol. Res., 1989, 21, 617.
Georg Suss-Fink, Arene ruthenium complexes as anticancer agents, Dalton Transactions, 39, 2010, 1673–1688.
H.-K. Liu, F. Wang, J. A. Perkinson, J. Bella and P. J. Sadler, Chem.–Eur. J., 2006, 12, 6151. H. Chen, J. A. Parkinson, R. E. Morris and P. J. Sadler, J. Am. Chem. Soc., 2003, 125, 173.
H. Chen, J. A. Parkinson, S. Parsons, R. A. Coxall, R. O. Gould and P. J. Sadler, J. Am. Chem. Soc., 2002, 124, 3064.
H. Keller and B. Keppler, US Patent, 1989, 4843069; cf. B.K. Keppler, K.-G. Lipponer, B. Stenzel and F. Kratzin, in, B. K. Keppler (editor), Metal Complexes in Cancer Chemotherapy, VCH, Weinheim, 1993, p. 187. I. Bratsos, S. Jedner, A. Bergamo, G. Sava, T. Gianferrara, E. Zangrando and Enzo Alessio, J. Inorg. Biochem. 2008, 102, 1120.
Ioannis Bratsos, a Elisa Mitri, a Francesco Ravalico, a Ennio Zangrando, a Teresa Gianferrara, a Alberta Bergamob and Enzo Alessio, New half sandwich Ru(II) coordination compounds for anticancer activity, Dalton Transactions, 41, 2012, 7358–7371.
J. R. Durig, J. Danneman, W. D. Behnke and E. E. Mercer, Chem.-Biol. Interact., 1976, 13, 287.
Jos´e Ruiz, a Consuelo Vicente, a Concepci´on de Haroa and Delia Bautistab, A novel ruthenium(II) arene based intercalator with potent anticancer activity, Dalton Transactions, 2009, 5071–5073.
L. Ronconi and P.J. Sadler, Coord. Chem. Rev., 2007, 251, 1633.
M. Melchart and P. J. Sadler, in, G. Jaouen (editor), Bioorganometallics, Wiley-VCH, Weinheim, 2006, p. 39.
M. J. Clarke, Met. Ions Biol. Syst., 1980, 11, 231.
M. Coluccia, G. Sava, F. Loseto, A. Nassi, A. Bocarelli, D. Giordano, E. Alessio and G. Mestroni, Eur. J. Cancer, 1993, 29, 1873.
M. J. Clarke, Coord. Chem. Rev., 2003, 236, 209.
M.-G. Mendoza-Ferri, C. G. Hartinger, R. E. Eichinger, N. Stolyarova, K. Severin, M. A. Jakupec, A. A. Nazarov and B. K. Keppler, Organometallics, 2008, 27, 2405.
M.-G.Mendoza-Ferri, C.G.Hartinger, A.A.Nazarov, W.Kandioller, K. Severin and B. K.Keppler, Appl. Organomet. Chem., 2008, 22, 326. M. Auzias, B. Therrien, G. S¨uss-Fink, P. ?St?epni?cka, W. H. Ang and P. J. Dyson, Inorg. Chem., 2008, 47, 578.
M. J. Clarke, F. Zhu and D. R. Frasca, Chem. Rev., 1999, 99, 2511.
M. S. Gordon, Chem